1,258 results match your criteria Journal of Clinical Lipidology [Journal]


Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review.

J Clin Lipidol 2018 Nov 3. Epub 2018 Nov 3.

Department of Paediatric Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands.

Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that may cause life-threatening cardiovascular disease (CVD) at childhood. Marginal effectiveness of statins in reducing low-density lipoprotein cholesterol (LDL-C) is the reason why extracorporeal removal of LDL-C by lipoprotein apheresis (LA) is recommended at the earliest possible age.

Objective: It is, however, unknown to what extent LA effectively reduces the burden of CVD in children with HoFH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.011DOI Listing
November 2018

Increased usual physical activity is associated with a blunting of the triglyceride response to a high-fat meal.

J Clin Lipidol 2018 Nov 20. Epub 2018 Nov 20.

Program in Personalized and Genomic Medicine, and Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.

Background: Postprandial lipemia (PPL), defined as a prolonged or elevated rise in triglycerides that accompanies fat feeding, is a significant risk factor for coronary heart disease and associated comorbidities. The impact of PPL on coronary heart disease risk is underscored by the preponderance of each day spent in the postprandial state.

Objective: In this study, we evaluated cross-sectionally the association between usual (ie, noninterventional) physical activity and the 6-hour triglyceride response to a standardized high-fat meal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.006DOI Listing
November 2018

Comparing patients' prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid.

J Clin Lipidol 2018 Nov 15. Epub 2018 Nov 15.

Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical Center, Kansas City, KS, USA; Division of Clinical Pharmacology, Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

Background: Dietary fish oil supplements containing the omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are frequently used for cardiovascular benefit. However, several factors may limit the intake of prescribed doses.

Objective: The objective of this study is to compare the prescribed, patient self-reported, and actual intake of supplemental EPA + DHA doses in a lipid-specialty clinic and identify common barriers and influences to therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.005DOI Listing
November 2018

Postprandial lipid absorption in seven heterozygous carriers of deleterious variants of MTTP in two abetalipoproteinemic families.

J Clin Lipidol 2018 Oct 24. Epub 2018 Oct 24.

Service de Biochimie métabolique, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix (AP-HP), Paris, France; Faculté de Pharmacie de Paris, Université Paris Descartes, Sorbonne Paris Cité, Unité de Technologies Chimiques et Biologiques pour la Santé, U 1022 INSERM, UMR 8258 CNRS, Paris, France.

Background: Abetalipoproteinemia, a recessive disease resulting from deleterious variants in MTTP (microsomal triglyceride transfer protein), is characterized by undetectable concentrations of apolipoprotein B, extremely low levels of low-density lipoprotein cholesterol in the plasma, and a total inability to export apolipoprotein B-containing lipoproteins from both the intestine and the liver.

Objective: To study lipid absorption after a fat load and liver function in 7 heterozygous relatives from 2 abetalipoproteinemic families, 1 previously unreported.

Results: Both patients are compound heterozygotes for p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.003DOI Listing
October 2018

Severe aortic valve stenosis in a 14-year-old boy with sitosterolemia.

J Clin Lipidol 2018 Nov 14. Epub 2018 Nov 14.

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

We report a 14-year-old boy finally diagnosed with sitosterolemia, presenting with severe aortic valve stenosis. Genetic analysis revealed homozygous null mutation c.1336 C > T (p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.002DOI Listing
November 2018

JCL roundtable-Lipoprotein(a): The emerging risk factor.

J Clin Lipidol 2018 Nov - Dec;12(6):1335-1345

Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

Lipoprotein(a), or Lp(a), is a major risk factor for atherothrombotic events along with low-density lipoprotein cholesterol and, inversely, high-density lipoprotein cholesterol. Lp(a) also contributes to the progression of calcific aortic stenosis and to the rare occurrence of arterial thrombotic strokes without atherosclerosis in children and younger women. Much has been learned about the inheritance of Lp(a) levels and the relationship between apolipoprotein(a) structure and function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.003DOI Listing
December 2018

From the editor: Lessons from the East.

Authors:
John R Guyton

J Clin Lipidol 2018 Nov - Dec;12(6):1331-1332

Professor of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.001DOI Listing
December 2018

Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.

J Clin Lipidol 2018 Nov 7. Epub 2018 Nov 7.

Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Background: Current data from individual studies present conflicting evidence about the relationship between risk factors and cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (FH).

Objectives: We conducted a systematic review and meta-analysis to quantify the association between various CVD risk factors and CVD in FH.

Methods: We searched MEDLINE, EMBASE, Global Health, the Cochrane Library, and PubMed for English-language studies reporting adjusted-associations between cardiovascular, behavioral, or clinical risk factors and CVD with ≥ 100 participants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.012DOI Listing
November 2018

Diagnostic accuracy of ultrasound and MRI for Achilles tendon xanthoma in people with familial hypercholesterolemia: A systematic review.

J Clin Lipidol 2018 Nov 7. Epub 2018 Nov 7.

Department of Medicine, Centre for Heart and Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Background: Achilles tendon xanthoma (ATX) results from tendon thickening and subclinical inflammation triggered by hypercholesterolemia, and is associated with more severe coronary artery disease and a higher risk of cardiovascular events. The ability to detect ATX by clinical examination is limited, and diagnostic imaging, for instance, using ultrasonography or magnetic resonance imagine (MRI), may improve the identification of ATX. However, the accuracy of ultrasound (US) imaging or MRI in identifying ATX in people with familial hypercholesterolemia (FH) has not been systematically reviewed. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183043
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.10.013DOI Listing
November 2018
4 Reads

GPIHBP1 autoantibody syndrome during interferon β1a treatment.

J Clin Lipidol 2018 Oct 24. Epub 2018 Oct 24.

Departments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address:

Background: Autoantibodies against glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) cause chylomicronemia by blocking the ability of GPIHBP1 to bind lipoprotein lipase (LPL) and transport the enzyme to its site of action in the capillary lumen.

Objective: A patient with multiple sclerosis developed chylomicronemia during interferon (IFN) β1a therapy. The chylomicronemia resolved when the IFN β1a therapy was discontinued. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.004DOI Listing
October 2018
1 Read

Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease.

J Clin Lipidol 2018 Oct 29. Epub 2018 Oct 29.

Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.

Background: Tendon xanthomas are accumulations of collagen and macrophages, which contain cholesterol esters and a marker of high risk for coronary artery disease (CAD).

Objective: The aim of the article was to clarify whether the presence of Achilles tendon thickening (ATT) was associated with disease severity and plaque vulnerability in patients with CAD.

Methods: A total of 241 consecutive patients who underwent percutaneous coronary intervention and ATT assessment were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.007DOI Listing
October 2018
1 Read

Severe hypertriglyceridemia is primarily polygenic.

J Clin Lipidol 2018 Oct 24. Epub 2018 Oct 24.

Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Electronic address:

Background: Hypertriglyceridemia (HTG) is a complex trait defined by elevated plasma triglyceride levels. Genetic determinants of HTG have so far been examined in a piecemeal manner; understanding of its molecular basis, both monogenic and polygenic, is thus incomplete.

Objective: The objective of this study was to characterize genetic profiles of patients with severe HTG, and quantify the genetic determinants and molecular contributors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.006DOI Listing
October 2018
7 Reads

Recurrent tendosynovitis as a rare manifestation of a lipid disorder.

J Clin Lipidol 2018 Oct 24. Epub 2018 Oct 24.

Department of Internal Medicine V (Nephrology, Rheumatology, Hypertensiology, Endocrinolgy, Diabetology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany; Mannheim Institute of Public Health, Social and Preventive Medicine, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany. Electronic address:

A 33-year-old female had suffered from spontaneously recurrent bursitis and tendosynovitis/enthesitis of the patellar and Achilles tendons for about 10 years. The episodes of immobilization increased. Ultrasound imaging of the swollen and painful tendons showed chronic inflammation with neoangiogenesis within the tendons and hypoechoic lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.005DOI Listing
October 2018
1 Read

Extremely high levels of high-density lipoprotein cholesterol and increased risk of cardiovascular mortality.

Authors:
Tomoyuki Kawada

J Clin Lipidol 2018 Nov - Dec;12(6):1550-1551. Epub 2018 Oct 30.

Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.010DOI Listing
October 2018

Response to the letter entitled "Extremely high levels of high-density lipoprotein cholesterol and increased risk of cardiovascular mortality" by Dr Kawada.

J Clin Lipidol 2018 Nov - Dec;12(6):1551. Epub 2018 Oct 31.

Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.009DOI Listing
October 2018

Predictors of statin use among older adults: A nationwide cross-sectional study.

J Clin Lipidol 2018 Oct 16. Epub 2018 Oct 16.

Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia. Electronic address:

Background: Statins comprise a key strategy for the prevention and treatment of arteriosclerotic cardiovascular disease, but prescribing remains suboptimal.

Objectives: The objective of this study was to characterize the predictors of statin use among adults aged ≥65 years.

Methods: A cross-sectional study using Pharmaceutical Benefits Scheme (PBS) data on reimbursed prescriptions for a 10% random sample of the Australian population in 2016 was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.002DOI Listing
October 2018
2 Reads

Coronary computed tomography angiogram in familial hypercholesterolemia: A double edge sword.

J Clin Lipidol 2018 Nov - Dec;12(6):1549. Epub 2018 Oct 9.

Monash Cardiovascular Research Centre, MonashHEART, Monash Health, Monash University, Melbourne, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183041
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.014DOI Listing
October 2018
2 Reads

Relationship between erythrocyte phospholipid fatty acid composition and obesity in children and adolescents.

J Clin Lipidol 2018 Sep 25. Epub 2018 Sep 25.

Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China; Institute of Nutrition & Health, Qingdao University, Qingdao, China. Electronic address:

Background: Observational studies have reported inconsistent results on the association between circulating fatty acids and obesity.

Objective: The objective of this study was to investigate the relationship between erythrocyte phospholipid fatty acid composition and obesity in children and adolescents.

Methods: We conducted a case-control study including 1442 obese and 1442 normal-weight children and adolescents. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183041
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.013DOI Listing
September 2018
4 Reads

Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1.

J Clin Lipidol 2018 Nov - Dec;12(6):1374-1382. Epub 2018 Sep 1.

Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie- Santé, Saint Joseph University, Beirut, Lebanon; INSERM LVTS U1148, Hôpital Bichat-Claude Bernard, Paris, France. Electronic address:

Background: The Middle East region is characterized by low levels of high-density lipoprotein cholesterol (HDL-C). To date, no genetic study has investigated the cause of low HDL-C in the Lebanese population.

Objective: Our objective was to study the genetic causes for hypoalphalipoproteinemia in a Lebanese family with extremely low HDL-C levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.013DOI Listing
September 2018
6 Reads

Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence.

J Clin Lipidol 2018 Sep 18. Epub 2018 Sep 18.

Boston Heart Diagnostics, Framingham, MA, USA. Electronic address:

Background: Triglyceride (TG) concentrations >2000 mg/dL are extremely elevated and increase the risk of pancreatitis.

Objectives: We characterized five cases and two kindreds and ascertained prevalence in a reference laboratory population.

Methods: Plasma lipids and DNA sequences of LPL, GPIHBP1, APOA5, APOC2, and LMF1 were determined in cases and two kindreds. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.007DOI Listing
September 2018
3 Reads

Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention.

J Clin Lipidol 2018 Sep 22. Epub 2018 Sep 22.

3rd Medical Department with Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria; Sigmund Freud University, Medical School, Vienna, Austria.

Background: Patients with familial hypercholesterolemia (FH) are at increased risk for premature and subsequent cardiovascular disease. Data on long-term major adverse cardiovascular events (MACE) in patients with FH after percutaneous coronary intervention (PCI) in the era of high-intensity statins are scarce.

Objective: We assessed the prognostic impact of clinically diagnosed FH on long-term MACE, a composite of all-cause death, myocardial infarction, and ischemic stroke in patients admitted for stable coronary artery disease (SCAD) or acute coronary syndromes (ACSs) undergoing PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.09.012DOI Listing
September 2018
3 Reads

In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction.

J Clin Lipidol 2018 Sep 21. Epub 2018 Sep 21.

L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France. Electronic address:

Background: Beyond the hepatobiliary pathway, studies have demonstrated that direct transintestinal cholesterol efflux (TICE) of plasma-derived cholesterol may contribute to reverse cholesterol transport. The clinical evidence of TICE in human remains challenged because of the difficulty to discriminate the hepatobiliary and transintestinal routes in vivo.

Objective: To provide the first proof of concept that TICE exists in vivo in humans by demonstrating that plasma labeled cholesterol can be excreted in the feces of patients with complete bile duct obstruction. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.010DOI Listing
September 2018
7 Reads

Decreased GlycA after lifestyle intervention among obese, prediabetic adolescent Latinos.

J Clin Lipidol 2018 Sep 22. Epub 2018 Sep 22.

Division of Endocrinology and Diabetes, Phoenix Children's Hospital, Phoenix, AZ, USA; Center for Health Promotion and Disease Prevention, College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA; Southwest Interdisciplinary Research Center, Arizona State University, Phoenix, AZ, USA.

Background: Obese youth with prediabetes are at increased risk for premature morbidity and mortality through multiple mechanisms, including increased systemic inflammation. GlycA is a novel measure of systemic inflammation that predicts type II diabetes, cardiovascular events, and all-cause mortality in adults.

Objective: The purpose of the present study was to examine changes in GlycA after lifestyle intervention among obese, prediabetic Latino youth. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.011DOI Listing
September 2018
5 Reads

Biphasic dyslipidemia in a patient with painless thyroiditis.

J Clin Lipidol 2018 Nov - Dec;12(6):1367-1370. Epub 2018 Sep 21.

Toranomon Hospital Saitama Clinic, Saitama, Japan; Center for Health Science, Toranomon Hospital, Tokyo, Japan.

In this case study, we followed the thyroid function and serum lipid levels of a patient with painless thyroiditis. Serum lipid levels were decreased during the hyperthyroid phase and elevated during the hypothyroid phase. Both serum lipid levels and thyroid function returned to normative values following a course of thyroid replacement treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.09.009DOI Listing
September 2018
1 Read

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia.

J Clin Lipidol 2018 Sep 17. Epub 2018 Sep 17.

Nutrition, Metabolism and Atherosclerosis Clinic, Institut de recherches cliniques de Montréal, Montreal, Québec, Canada; Division of Medical Biochemistry, Department of Medicine, McGill University, Montreal, Québec, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Québec, Canada. Electronic address:

Background: Familial hypercholesterolemia (FH) is the most common genetic disorder of lipoprotein metabolism, affecting 1:250 individuals worldwide. This monogenic disease is associated with lifelong elevation in circulating low-density lipoprotein cholesterol and premature cardiovascular disease (CVD). In 2016, the estimated prevalence of diabetes in Canada was 9%. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.008DOI Listing
September 2018
5 Reads

The spectrum of type III hyperlipoproteinemia.

J Clin Lipidol 2018 Nov - Dec;12(6):1383-1389. Epub 2018 Sep 14.

Centre Hospitalier de l'Universite Laval, Quebec, Quebec, Canada.

Background: Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia characterized by hypercholesterolemia and hypertriglyceridemia due to markedly increased numbers of cholesterol-enriched chylomicron and very-low-density lipoprotein (VLDL) remnant lipoprotein particles. Type III can be distinguished from mixed hyperlipidemia based on a simple diagnostic algorithm, which involves total cholesterol, triglycerides, and apolipoprotein B (apoB). However, apoB is not measured routinely. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.006DOI Listing
September 2018
10 Reads

A failure of standardization or a failure of the process of standardization.

J Clin Lipidol 2018 Sep - Oct;12(5):1325-1326. Epub 2018 May 18.

Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.009DOI Listing

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

J Clin Lipidol 2018 Sep - Oct;12(5):1234-1243.e5. Epub 2018 May 31.

Department of Medicine, University California San Diego, La Jolla, CA, USA.

Background: Familial chylomicronemia syndrome (FCS) is a rare metabolic disorder caused by mutations in lipoprotein lipase (LPL) or genes required for LPL functionality and is characterized by hyperchylomicronemia that results in recurrent episodes of acute pancreatitis. Owing to the rarity of FCS, there are few case series describing the phenotypic variability in FCS patients in detail.

Objective: To provide baseline characteristics in the largest study population to date of patients with FCS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183024
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.05.013DOI Listing
May 2018
8 Reads

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.

J Clin Lipidol 2018 Sep - Oct;12(5):1199-1207. Epub 2018 May 22.

Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Background: Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is safe and effective in reducing low-density lipoprotein cholesterol in adults with familial hypercholesterolemia. A dedicated study, HAUSER-RCT, is being conducted to examine the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH).

Objective: To present the rationale and design of the HAUSER-RCT study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.007DOI Listing
May 2018
3 Reads

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

J Clin Lipidol 2018 Sep - Oct;12(5):1141-1145. Epub 2018 Jun 1.

Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduces low-density lipoprotein cholesterol levels and improves cardiovascular outcomes. Given the short time frame, these agents have been available for use; reports of nonresponse to the PCSK9 inhibitor therapy are scarce in literature. We describe 2 cases with substantially lesser than expected low-density lipoprotein cholesterol lowering on PCSK9 therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.017DOI Listing

The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis.

J Clin Lipidol 2018 Sep - Oct;12(5):1133-1140.e15. Epub 2018 Jun 13.

Monash Cardiovascular Research Centre, Monash Heart, Monash Health, Monash University, Melbourne, Australia.

Background: Current guidelines recommend an intensive lipid-lowering therapy to achieve the low-density lipoprotein cholesterol (LDL-C) target in patients with high risk of cardiovascular disease. Former studies suggested adding ezetimibe to statin therapy in the above setting may promote plaque changes; however, this effect has not been consistently reported.

Methods: Electronic searches were performed in MEDLINE, EMBASE, and Cochrane library on November 30, 2017 to identify prospective trials assessing the effects of combined ezetimibe and statin therapy versus statin therapy alone on atheroma volume using intravascular ultrasound. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.06.001DOI Listing
June 2018
1 Read

PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?

J Clin Lipidol 2018 Sep - Oct;12(5):1123-1132. Epub 2018 May 31.

Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Perugia, Italy.

The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183024
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.05.012DOI Listing
May 2018
2 Reads

"Taking a look under the hood"-imaging the phenotypic heterogeneity of familial hypercholesterolemia.

J Clin Lipidol 2018 Sep - Oct;12(5):1095-1098. Epub 2018 Jun 8.

Oregon Health & Science University, Knight Cardiovascular Institute, Center for Preventive Cardiology, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.020DOI Listing
June 2018
2 Reads

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

J Clin Lipidol 2018 Nov - Dec;12(6):1358-1366. Epub 2018 Sep 11.

Robarts Research Institute, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. Electronic address:

Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease. The principal evidence base for this comes from large population studies focusing on first atherothrombotic events. However, inconsistent findings have been reported from studies investigating the impact of elevated Lp(a) on atherothrombotic events in subjects with preexisting cardiovascular disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183037
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.08.012DOI Listing
September 2018
4 Reads

Low LDL-C and risk of hemorrhagic stroke in Chinese adults.

Authors:
Rachel H Mackey

J Clin Lipidol 2018 Sep - Oct;12(5):1111-1112. Epub 2018 Oct 9.

Assistant Professor of Epidemiology, University of Pittsburgh Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.09.003DOI Listing
October 2018

JCL roundtable: High-density lipoprotein function and reverse cholesterol transport.

J Clin Lipidol 2018 Sep - Oct;12(5):1086-1094. Epub 2018 Oct 9.

Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

High-density lipoproteins (HDL) have been known since the 1960s to be associated with protection from atherosclerotic cardiovascular disease. However, the mechanisms of this protection are unclear. The extent to which HDL per se vs other correlated metabolic factors may mitigate atherosclerosis has been seriously questioned. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183038
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.005DOI Listing
October 2018
6 Reads

From the editor: What is the bottom line for clinical lipidology research?

Authors:
John R Guyton

J Clin Lipidol 2018 Sep - Oct;12(5):1083-1084. Epub 2018 Oct 9.

Professor of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.09.004DOI Listing
October 2018
1 Read

Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study.

J Clin Lipidol 2018 Sep 6. Epub 2018 Sep 6.

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; CCRE Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Background: There is currently insufficient evidence to support the use of lipid-lowering drug treatment (LLT) for primary prevention of cardiovascular disease (CVD) in the elderly.

Objectives: We examined the relationship of early initiation of LLT with short- and long-term all-cause and CVD mortality in persons older than 65 years in this post hoc study from the Second Australian National Blood Pressure study (ANBP2).

Methods: This was an in- and post-trial observational study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183037
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.08.014DOI Listing
September 2018
2 Reads

Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting.

J Clin Lipidol 2018 Nov - Dec;12(6):1452-1462. Epub 2018 Sep 7.

Institut de Recerca - Hospital de la Santa Creu i Sant Pau, Serveis de Bioquímica, i d'Endocrinologia i Nutrició, IIB Sant Pau, CIBERDEM, Universitat Autònoma de Barcelona, Departaments de Bioquímica i Biologia Molecular, i Medicina, Barcelona, Spain. Electronic address:

Background: Autosomal dominant hypercholesterolemia (ADH) is associated with mutations in the low-density lipoprotein (LDL) receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) genes, and it is estimated to be greatly underdiagnosed. The most cost-effective strategy for increasing ADH diagnosis is a cascade screening from mutation-positive probands.

Objective: The objective of this study was to evaluate the results from 2008 to 2016 of ADH genetic analysis performed in our clinical laboratory, serving most lipid units of Catalonia, a Spanish region with approximately 7. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183037
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.002DOI Listing
September 2018
3 Reads

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.

J Clin Lipidol 2018 Nov - Dec;12(6):1463-1470. Epub 2018 Aug 30.

Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.

Background: ODYSSEY OLE (NCT01954394) was an open-label extension (OLE) study for patients with heterozygous familial hypercholesterolemia (HeFH) who had completed previous phase 3 clinical trials with alirocumab. Alirocumab dose could be increased or decreased as per physician judgment.

Objective: To assess how the alirocumab dosing strategy was used by physicians during OLE. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183037
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.08.011DOI Listing
August 2018
1 Read

Integrating lipid screening with ideal cardiovascular health assessment in pediatric settings.

J Clin Lipidol 2018 Nov - Dec;12(6):1346-1357. Epub 2018 Aug 29.

Department of Pediatrics, Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, Fort Worth, TX, USA.

Pediatric lipid screening and management with the aim of reducing and preventing adult disease is an internationally accepted concept, and guidelines have been published in several countries. However, implementation by the practicing pediatric community in the United States has been less than expected and delays have been attributed to uncertainty among providers. Reduced screening rates have also been reported for conditions contributing to arterial wall pathology such as obesity, hypertension, and prediabetes despite accumulating evidence that detection and intervention can lead to risk reversal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.009DOI Listing
August 2018
6 Reads

Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.

J Clin Lipidol 2018 Nov - Dec;12(6):1493-1501.e11. Epub 2018 Aug 29.

Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA. Electronic address:

Background: Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk.

Objective: To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events.

Methods: apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.010DOI Listing
August 2018
3 Reads

Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins.

J Clin Lipidol 2018 Nov - Dec;12(6):1539-1548. Epub 2018 Aug 27.

Division of Biomedical Informatics, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, USA.

Background: Traditionally, the impact of lipoproteins on vascular disease has been evaluated in light of their quantity, that is, cholesterol content, in plasma. However, recent studies of high-density lipoproteins (HDLs) have focused on functionality with regard to atheroprotection. For example, bioassays have emerged to assess the ability of HDL, in its near native plasma environment, to promote cholesterol removal (efflux) from cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.007DOI Listing
August 2018
1 Read

Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease.

J Clin Lipidol 2018 Nov - Dec;12(6):1436-1444. Epub 2018 Aug 23.

Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.

Background: The genetic background of severe familial hypercholesterolemia (FH) has yet to be determined.

Objective: We tested if genetic variants associated with low-density lipoprotein (LDL)-altering autosomal recessive diseases influenced LDL cholesterol levels and the odds for coronary artery disease in patients with high LDL cholesterol.

Methods: We recruited 500 individuals with elevated LDL cholesterol levels (≥180 mg/dL or ≥140 mg/dL for subjects <15 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.006DOI Listing
August 2018
1 Read

Differences in heme and hemopexin content in lipoproteins from patients with sickle cell disease.

J Clin Lipidol 2018 Nov - Dec;12(6):1532-1538. Epub 2018 Aug 14.

Hematology and Hemotherapy Center, University of Campinas-UNICAMP, Campinas, Brazil; Division of Hematology, University of Washington, Seattle, WA, USA. Electronic address:

Background: High blood cholesterol is associated with atherogenesis and endothelial dysfunction. The latter is present in hemolytic diseases, such as sickle cell anemia, whose carriers have hypocholesterolemia and low incidence of coronary artery disease.

Objective: We aimed to characterize cholesterol fractions in patients with sickle cell disease and explore the relationship among lipoproteins, varying degrees of hemolysis, and its biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.002DOI Listing
August 2018
2 Reads

Retinal microvascular dysfunction in hypercholesterolemia.

J Clin Lipidol 2018 Nov - Dec;12(6):1523-1531.e2. Epub 2018 Aug 18.

Cardiology, University Heart Center Zurich, University Hospital Zurich, Zurich, Switzerland. Electronic address:

Background: Hypercholesterolemia is one of the most important contributors to atherosclerosis. Whether hypercholesterolemia also affects the retinal microcirculation is unclear.

Objective: The goal of our study was to assess the association of cholesterol levels with retinal microvascular function using dynamic and static retinal vessel analysis (RVA) in a primary prevention setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.07.015DOI Listing
August 2018
1 Read

Paradoxical fall in proteinuria during pregnancy in an LCAT-deficient patient-A case report.

J Clin Lipidol 2018 Sep - Oct;12(5):1151-1156. Epub 2018 Jul 21.

Renal Unit, Antrim Hospital, Northern Health and Social Care Trust, Antrim, Northern Ireland, UK.

A 29-year-old lady was diagnosed with lecithin:cholesterol acyltransferase (LCAT) deficiency having presented with bilateral corneal clouding, severely reduced high density lipoproteins cholesterol, and proteinuria. She is a compound heterozygote with two LCAT gene mutations, one of which is novel, c.321C>A in exon 3. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183026
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.06.006DOI Listing
July 2018
10 Reads

Circulating oleic acid levels are related to greater risks of cardiovascular events and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis.

J Clin Lipidol 2018 Nov - Dec;12(6):1404-1412. Epub 2018 Aug 16.

Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, MN, USA. Electronic address:

Background: Limited evidence has suggested that circulating levels of the omega-9 fatty acid, oleic acid, may be related to greater risks of adverse cardiovascular outcomes.

Objective: We aimed to determine whether plasma oleic acid may be independently associated with clinical and subclinical cardiovascular disease (CVD) and all-cause mortality in a large multiethnic cohort.

Methods: Plasma fatty acids were measured by gas chromatography-flame ionization in 6568 participants of the Multi-Ethnic Study of Atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289878PMC
August 2018
1 Read

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.

J Clin Lipidol 2018 Nov - Dec;12(6):1390-1403.e4. Epub 2018 Aug 10.

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Background: Treatment with omega-3 fatty acids and fenofibrates reduces serum triglyceride levels, but few studies have compared the effect of these agents on liver fat.

Objective: The aim of the EFFECT I trial (NCT02354976) was to determine the effects of free omega-3 carboxylic acids (OM-3CA) and fenofibrate on liver fat in overweight or obese individuals with non-alcoholic fatty liver disease and hypertriglyceridemia.

Methods: Seventy-eight patients were randomized to receive oral doses of 4 g OM-3CA (n = 25), 200 mg fenofibrate (n = 27), or placebo (n = 26) for 12 weeks in a double-blind, parallel-group study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.003DOI Listing
August 2018
1 Read